Progesterone transdermal

Scarabin PY. The effects of transdermal and oral estro-gen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost... 

Oral post-menopausal estrogen replacement therapy increases circulating concentrations of C-reactive protein, but in 68 women who took a combination of transdermal 17-beta-estradiol and micronized progesterone there was no significant effect of transdermal estrogen on C-reactive protein concentrations compared with placebo (86). 

Therapeutically used types of estrogens and prog-estins are listed in Tables 30-4 and 30-5. Both types of hormones can be administered in their natural form (estradiol and progesterone), and several synthetic derivatives of each type are also available. Most of the drugs listed in Tables 30-4 and 30-5 are available as oral preparations, and many conditions can be conveniently treated by oral administration. These hormones may also be administered transdermally via patches, creams, or gels the transdermal route may offer certain advantages, such as decreased side effects and liver problems.86,130 Certain preparations can be... 

Cicinelli E, de Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules a 3-year pilot study. Fertil Steril. 2005 83 1859-1863. 

The use of conventional topical formulations for transdermal drag delivery is presently limited to classic ointments for nitroglycerin, and some gel formulations of estradiol and progesterone. Although of demonstrated efficacy, these vehicles are often inelegant and result in poor reproducibility of the delivered dose (and hence of the provoked pharmacological effect). This variability, of course, originates in the... 

Fig. 18 (Upper panel) The 4—week serum levonorgestrel profiles in 12 human volunteers, each receiving 1 or 2 units of a transdermal contraceptive system (10 cm, with daily dosage of 28.3 pg/day) once a week, consecutively for 3 weeks, and the same size of placebo on week 4. (Lower panel) Comparative serum concentration profiles of progesterone during the pretreatment and treatment cycles in two subjects, each as the representative for group A (receiving lOcm ) and group B (receiving 20 cm ), respectively. The suppression of progesterone peak during the treatment cycle is an indication of effective fertility control.

Valenta C, Walzer A, Clausen AE, Bernkop-Schnurch A. Thiolated polymers development and evaluation of transdermal delivery systems for progesterone. Pharm Res 2001 18(2) 211—216. 

Estradiol 100-200 meg transdermal patch every 3-7 days with add-back progesterone... 

Wren BG, Champion SM, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003 10 13-18. 

---